Aptorum Group Limited (APM)
NASDAQ: APM · Real-Time Price · USD
0.877
-0.019 (-2.07%)
At close: Apr 28, 2026, 4:00 PM EDT
0.880
+0.003 (0.34%)
Pre-market: Apr 29, 2026, 4:10 AM EDT
Aptorum Group Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
7.14M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 4.99M |
| Xenetic Biosciences | 2.98M |
| BioAtla | 2.00M |
| Addex Therapeutics | 198.82K |
| Silo Pharma | 72.10K |
APM News
- 7 weeks ago - Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania - GlobeNewsWire
- 3 months ago - Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease - GlobeNewsWire
- 5 months ago - DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference - GlobeNewsWire
- 7 months ago - Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering - GlobeNewsWire
- 7 months ago - As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives - GlobeNewsWire
- 8 months ago - Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 8 months ago - Why Is Nano-Cap Aptorum Stock Rallying On Thursday? - Benzinga
- 8 months ago - DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test - GlobeNewsWire